



Respiratory Syncytial Virus (RSV) Vaccines Arexvy™ and Abrysvo™ Now on the Contract Drugs List

October 3, 2023

Effective October 1, 2023, Arexvy and Abrysvo are included on the [Medi-Cal Rx Contract Drugs List](#) and available without a prior authorization (PA), but restricted to the U.S. Food and Drug Administration (FDA) indications.

- **Arexvy** is indicated for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
- **Abrysvo** is indicated for active immunization of pregnant individuals at 32 to 36 weeks gestational age for the prevention of lower respiratory tract disease caused by RSV in infants from birth to 6 months. It is also indicated for active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@magellanhealth.com.